Breast biomarker immunocytochemistry

Soheila Korourian, Asangi R. Kumarapeli, Vicki Klimberg

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Organization, more than 20 morphologic subtypes of breast cancer have been recognized. By gene expression, invasive breast cancer is classified into at least four major subtypes; luminal A, luminal B, human epidermal growth factor receptor 2 (HER2)/neu-positive, and triple-negative cancers. The biology and the prognosis of these subtypes are vastly different. It is well recognized that genetic profiles of these cancer subtypes are also interlinked with the traditional breast biomarkers. According to the US National Institutes of Health's Working Group and Biomarkers Consortium, a biomarker is a characteristic that is objectively measured as an indicator of normal biological processes, pathogenic processes, or a pharmacologic response to a therapeutic intervention.

Original languageEnglish (US)
Title of host publicationThe Breast
Subtitle of host publicationComprehensive Management of Benign and Malignant Diseases
PublisherElsevier Inc.
Pages197-206.e6
ISBN (Print)9780323359559
DOIs
StatePublished - Aug 24 2017

Fingerprint

Breast
Biomarkers
Immunohistochemistry
Breast Neoplasms
Biological Phenomena
National Institutes of Health (U.S.)
Neoplasms
Organizations
Gene Expression
Therapeutics
human ERBB2 protein

Keywords

  • Biomarker
  • Hormone receptors
  • Immunohistochemistry
  • Pathology

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Korourian, S., Kumarapeli, A. R., & Klimberg, V. (2017). Breast biomarker immunocytochemistry. In The Breast: Comprehensive Management of Benign and Malignant Diseases (pp. 197-206.e6). Elsevier Inc.. https://doi.org/10.1016/B978-0-323-35955-9.00014-3

Breast biomarker immunocytochemistry. / Korourian, Soheila; Kumarapeli, Asangi R.; Klimberg, Vicki.

The Breast: Comprehensive Management of Benign and Malignant Diseases. Elsevier Inc., 2017. p. 197-206.e6.

Research output: Chapter in Book/Report/Conference proceedingChapter

Korourian, S, Kumarapeli, AR & Klimberg, V 2017, Breast biomarker immunocytochemistry. in The Breast: Comprehensive Management of Benign and Malignant Diseases. Elsevier Inc., pp. 197-206.e6. https://doi.org/10.1016/B978-0-323-35955-9.00014-3
Korourian S, Kumarapeli AR, Klimberg V. Breast biomarker immunocytochemistry. In The Breast: Comprehensive Management of Benign and Malignant Diseases. Elsevier Inc. 2017. p. 197-206.e6 https://doi.org/10.1016/B978-0-323-35955-9.00014-3
Korourian, Soheila ; Kumarapeli, Asangi R. ; Klimberg, Vicki. / Breast biomarker immunocytochemistry. The Breast: Comprehensive Management of Benign and Malignant Diseases. Elsevier Inc., 2017. pp. 197-206.e6
@inbook{6e6792d3c2a94c71988ae53be8c9ee6f,
title = "Breast biomarker immunocytochemistry",
abstract = "Organization, more than 20 morphologic subtypes of breast cancer have been recognized. By gene expression, invasive breast cancer is classified into at least four major subtypes; luminal A, luminal B, human epidermal growth factor receptor 2 (HER2)/neu-positive, and triple-negative cancers. The biology and the prognosis of these subtypes are vastly different. It is well recognized that genetic profiles of these cancer subtypes are also interlinked with the traditional breast biomarkers. According to the US National Institutes of Health's Working Group and Biomarkers Consortium, a biomarker is a characteristic that is objectively measured as an indicator of normal biological processes, pathogenic processes, or a pharmacologic response to a therapeutic intervention.",
keywords = "Biomarker, Hormone receptors, Immunohistochemistry, Pathology",
author = "Soheila Korourian and Kumarapeli, {Asangi R.} and Vicki Klimberg",
year = "2017",
month = "8",
day = "24",
doi = "10.1016/B978-0-323-35955-9.00014-3",
language = "English (US)",
isbn = "9780323359559",
pages = "197--206.e6",
booktitle = "The Breast",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Breast biomarker immunocytochemistry

AU - Korourian, Soheila

AU - Kumarapeli, Asangi R.

AU - Klimberg, Vicki

PY - 2017/8/24

Y1 - 2017/8/24

N2 - Organization, more than 20 morphologic subtypes of breast cancer have been recognized. By gene expression, invasive breast cancer is classified into at least four major subtypes; luminal A, luminal B, human epidermal growth factor receptor 2 (HER2)/neu-positive, and triple-negative cancers. The biology and the prognosis of these subtypes are vastly different. It is well recognized that genetic profiles of these cancer subtypes are also interlinked with the traditional breast biomarkers. According to the US National Institutes of Health's Working Group and Biomarkers Consortium, a biomarker is a characteristic that is objectively measured as an indicator of normal biological processes, pathogenic processes, or a pharmacologic response to a therapeutic intervention.

AB - Organization, more than 20 morphologic subtypes of breast cancer have been recognized. By gene expression, invasive breast cancer is classified into at least four major subtypes; luminal A, luminal B, human epidermal growth factor receptor 2 (HER2)/neu-positive, and triple-negative cancers. The biology and the prognosis of these subtypes are vastly different. It is well recognized that genetic profiles of these cancer subtypes are also interlinked with the traditional breast biomarkers. According to the US National Institutes of Health's Working Group and Biomarkers Consortium, a biomarker is a characteristic that is objectively measured as an indicator of normal biological processes, pathogenic processes, or a pharmacologic response to a therapeutic intervention.

KW - Biomarker

KW - Hormone receptors

KW - Immunohistochemistry

KW - Pathology

UR - http://www.scopus.com/inward/record.url?scp=85054329014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054329014&partnerID=8YFLogxK

U2 - 10.1016/B978-0-323-35955-9.00014-3

DO - 10.1016/B978-0-323-35955-9.00014-3

M3 - Chapter

AN - SCOPUS:85054329014

SN - 9780323359559

SP - 197-206.e6

BT - The Breast

PB - Elsevier Inc.

ER -